Zydus completes Sterling Biotech API business buy

Zydus Lifesciences Limited (ZYDUSLIFE) has completed the acquisition of the API business of Sterling Biotech Limited. The deal follows completion of conditions precedent and closing date adjustments. The acquisition is based on the Business Transfer Agreement dated September 17, 2024. The transaction transfers the API business of Sterling Biotech to Zydus Lifesciences. The company has confirmed the closing of the deal after fulfilling all required conditions under the agreement. The key triggers are the completion of the Sterling Biotech API business acquisition and the fulfilment of conditions under the September 2024 agreement. This strengthens Zydus’s API manufacturing capabilities and product portfolio in fermentation-based ingredients. Peers such as Sun Pharma, Divi's Laboratories and Laurus Labs may face comparison on API capacity and backward integration. Near-term prices could react positively to the successful closure of the long-pending deal. Risks include integration challenges or slower-than-expected contribution from the acquired assets. Competitors listed: Sun Pharma, Divi's Laboratories, Laurus Labs. We have no financial interest in this news.